CN105601626A - 一种含2-取代噁唑啉衍生物的制备方法 - Google Patents

一种含2-取代噁唑啉衍生物的制备方法 Download PDF

Info

Publication number
CN105601626A
CN105601626A CN201510745883.3A CN201510745883A CN105601626A CN 105601626 A CN105601626 A CN 105601626A CN 201510745883 A CN201510745883 A CN 201510745883A CN 105601626 A CN105601626 A CN 105601626A
Authority
CN
China
Prior art keywords
preparation
formula
cdcl
substituted oxazole
quinoline derivant
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201510745883.3A
Other languages
English (en)
Inventor
陆展
席拓
梅运才
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Zhejiang University ZJU
Original Assignee
Zhejiang University ZJU
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zhejiang University ZJU filed Critical Zhejiang University ZJU
Priority to CN201510745883.3A priority Critical patent/CN105601626A/zh
Publication of CN105601626A publication Critical patent/CN105601626A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/08—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D263/10—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/08—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D263/10—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D263/12—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms with radicals containing only hydrogen and carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/08—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D263/10—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D263/14—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms with radicals substituted by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic System
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6527—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07F9/653—Five-membered rings

Abstract

本发明公开一种含2-取代噁唑啉衍生物的制备方法，在有机溶剂中，将式I所示的卤化物，式II所示的噁唑啉环，钯催化剂，配体与碱以1:1-2.0:1％-50mol％:1％-50mol％:1-5的配比混合均匀，在0-150温度下反应24-72小时，分离纯化产物，得到式III所示的2-取代的噁唑啉化合物，本发明提供了一条高效快速合成含2-取代的噁唑啉化合物的路线，使用了催化量的钯和配体，反应可以高产率，高适用性的进行，立体专一性，可以得到对映体纯的2-取代的噁唑啉化合物，合成的目标产物可以直接作为不对称催化的配体。

Description

一种含2-取代噁唑啉衍生物的制备方法
技术领域
本发明涉及一种化学制备方法，具体地说，是一种含2-取代噁唑啉衍生物的制备方法。
背景技术
在不对催化领域，含噁唑啉化合物被广泛应用于不对称催化反应中((a)A.K.Ghosh,P.Mathivanan,J.Cappiello,Tetrahedron:Asymmetry1998,9,1-45；(b)J.S.Johnson,D.A.Evans,Acc.Chem.Res.2000,33,325-335；(c)G.Helmchen,A.Pfaltz,Acc.Chem.Res.2000,33,336-345；(d)P.Braunstein,F.Naud,Angew.Chem.Int.Ed.2001,40,680-699；(e)H.A.McManus,P.J.Guiry,Chem.Rev.2004,104,4151-4202；(f)G.Desimoni,G.Faita,K.A.Chem.Rev.2006,106,3561-3651；(g)G.C.Hargaden,P.J.Guiry,Chem.Rev.2009,109,2505-2550.)，合成含噁唑啉化合物的方法主要有两种路线，第一种从羧酸出发，与氯化亚砜反应得到酰氯，与手性氨基醇反应后，再与氯化亚砜氯化，碱性条件下关环得到取代手性噁唑啉化合物；第二种使用有机氰化物与手性氨基醇的路易斯酸催化下，缩合关环得到取代手性噁唑啉化合物。第一种方法使用了大量氯化亚砜且步骤过长，对一些敏感官能团不适用，第二种方法使用到价格高且剧毒物有机氰化物，也难以广泛应用。本发明人发明含2-取代噁唑啉衍生物(III)的制备方法。具体涉及sp2碳卤化物(I)与简单噁唑啉(II)在钯催化下，立体专一性合成2-取代噁唑啉衍生物(III)的方法。
发明内容
本发明所要解决的问题在于克服现有2-取代噁唑啉化合物合成方法存在的缺点，提供一种钯催化下，有机溶剂介质中，由简单的手性噁唑啉环与卤化物在碱性条件下，发生C-H键直接官能团化，立体专一性的得到据有关学活性的2-取代噁唑啉化合物。
本发明是通过以下技术方案来实现的：
本发明公开了一种含2-取代噁唑啉衍生物的制备方法，，在有机溶剂中，将式I所示的卤化物，式II所示的噁唑啉环，钯催化剂，配体与碱以1:1-2.0:1％-50mol％:1％-50mol％:1-5的配比混合均匀，在0-150℃温度下反应24-72小时，分离纯化产物，得到式III所示的2-取代的噁唑啉化合物，合成路线如下所示：
式I和式III中R1为C1-C6的烷基，环烷基，羟基，C1-C6的烷氧基，羟甲基，氰基，卤素，二芳基磷基，亚胺基，胺基，氨烷基；式II和式III中R2，R3和R4为C1-C6的烷基，环烷基，芳基；式I和式III中X为卤素,类卤素，Y为N或C。
作为进一步地改进，本发明所述的钯催化剂为Pd(PPh3)4，PdCl2，PdCl2(PPh3)2，Pd(OAc)2，Pd(PPh3)2Cl2，Pd2(dba)3·CHCl3任意一种，所述配体为单磷配体和双膦配体，所述碱为无机碱，所述有机溶剂为高沸点非极性溶剂。
作为进一步地改进，本发明所述的式I所示的卤化物与式II所示的噁唑啉环，钯催化剂，配体，碱摩尔比优选1:1.2-1.5:2.5-10mol％:2.8-12mol％,2.0-4.0。
作为进一步地改进，本发明所述的X优选Cl，Br。
作为进一步地改进，本发明所述的Pd优选Pd(OAc)2。
作为进一步地改进，本发明所述的配体优选dppe。
作为进一步地改进，本发明所述的碱优选叔丁醇锂。
作为进一步地改进，本命发明所述的有机溶剂优选1,4-二氧六环。
本发明优点在于：
1)提供了一条高效快速合成含2-取代的噁唑啉化合物的路线。
2)使用了催化量的钯和配体，反应可以高产率，高适用性的进行。
3)本反应是立体专一性，可以得到对映体纯的2-取代的噁唑啉化合物。
4)合成的的目标产物可以直接作为不对称催化的配体。
具体实施方式
本发明提供了一种2-取代噁唑啉化合物的制备方法，在有机溶剂中，将式I所示的卤化物与式II所示的噁唑啉环，钯催化剂，配体，碱摩尔比为1:1-2.0:1％-50％:1％-50％:1-5混合均匀，在0-150℃反应24-72小时，分离纯化产物，得到式III所示的2-取代的噁唑啉化合物，合成路线如下所示：
式I和式III中R1为C1-C6的烷基，环烷基，羟基，C1-C6的烷氧基，羟甲基，氰基，卤素，二芳基磷基，亚胺基，胺基；式II和式III中R2，R3和R4为C1-C6的烷基，环烷基；式I和式III中X为卤素，Y为N或C。Pd为Pd(PPh3)4，PdCl2、PdCl2(PPh3)2，Pd(OAc)2、Pd(PPh3)2Cl2，Pd2(dba)3·CHCl3，优选Pd(OAc)2；配体为单磷配体和双膦配体，优选dppe；碱为无机碱，优选叔丁醇锂；溶剂为高沸点非极性溶剂，优选1,4-二氧六环。
本发明式I所示的卤化物与式II所示的噁唑啉环，钯催化剂，配体，碱摩尔比优选1:1.2-1.5:2.5-10mol％:2.8-12mol％,2.0-4.0.
本发明产物III中当Y为R1含为杂原子取代时，可以作为不对称催化良好的配体，并得到广泛应用，如式IV-VIII((a)J.Chen,T.Xi,Z.Lu,Org.Lett.2014,16,6452-6455.(b)J.Guo,J.Chen,Z.Lu,Chem.Commun.2015,51,5725-5727；(c)S.L.Sedinkin,N.P.Rath,E.B.Bauer,J.Organomet.Chem.2008.683,3081-3091)。
发明人通过实验发现，杂环/芳环上不管为吸电子还是给电子取代基，反应都可快速高效进行，式I含有活拨氢取代基时，需要适当提高碱的量和反应时间，也可以有效进行。
下面通过具体实施例对本发明的技术方案作进一步地说明，以下实施例解释本发明，所有反应在无空气的氩气和脱气的溶剂中进行，但并不限制本发明内容。
实施：式I是市售可得的，式(II)的制备通过已知文献步骤合成(W.R.Leonard,J.L.Romine,A.I.Meyers,J.Org.Chem.1991,56,1961-1963.)。
2-取代噁唑啉的化合物III的制备：
氮气保护下，式I(1mmol,1equiv)与(S)-噁唑啉环(1.2equiv)在6mL二氧六环中，醋酸钯(2.5mol％)，Xantphos(2.8mol％)，叔丁醇钾(2.0equiv)，100度反应24小时，石油醚/乙酸乙酯过柱，得到2-取代的噁唑啉化合物式III。
实例1
(S,E)-N-(1-(6-(4-(tert-butyl)-4,5-dihydrooxazol-2-yl)pyridin-2-yl)ethylidene)-2,6-dimethylaniline(IIIa):yield86％；[α]D 20＝-44.7(c＝1.09,CHCl3)；IR(neat):2956,2869,1645,1573,1467,1367cm-1；1HNMR:(400.1MHz,CDCl3)δ8.50(dd,J＝8.0,0.8Hz,1H),8.22(dd,J＝8.0,0.8Hz,1H),7.87(t,J＝8.0Hz,1H),7.06(d,J＝7.6Hz,2H),6.93(t,J＝7.6Hz,1H),4.49(dd,J＝10.2,8.6Hz,1H),4.35(t,J＝8.6Hz,1H),4.15(dd,J＝10.2,8.6Hz,1H),2.26(s,3H),2.024(s,3H),2.019(s,3H),1.00(s,9H)；13CNMR:(100.6MHz,CDCl3)δ167.0,162.5,156.1,148.6,146.1,136.8,127.8,125.4,125.22,125.18,123.00,122.97,76.3,69.3,33.9,25.9,17.82,17.80,16.5；HRMS(EI)calculatedfor[C22H27N3O]+requiresm/z349.2154,foundm/z349.2157.
实例2
(S,E)-N-(1-(6-(4-isopropyl-4,5-dihydrooxazol-2-yl)pyridin-2-yl)ethylidene)-2,6-dimethylaniline(IIIb):yiel74％；[α]D 20＝-49.0(c＝1.06,CHCl3)；IR(neat):2959,2923,1644,1573,1466,1369cm-1；1HNMR:(400.1MHz,CDCl3)δ8.50(dd,J＝8.0,0.8Hz,1H),8.19(dd,J＝7.6,0.8Hz,1H),7.88(dd,J＝8.0,7.6Hz,1H),7.06(d,J＝7.6Hz,2H),6.94(t,J＝7.6Hz,1H),4.55(dd,J＝9.4,8.2Hz,1H),4.29-4.15(m,2H),2.26(s,3H),2.02(s,6H),1.97-1.85(m,1H),1.08(d,J＝6.8Hz,3H),0.97(d,J＝6.8Hz,3H)；13CNMR:(100.6MHz,CDCl3)δ167.0,162.6,156.2,148.6,146.0,136.9,127.8,125.33,125.26,125.2,123.1,123.0,72.9,70.8,32.8,19.1,18.2,17.9,16.6；HRMS(EI)calculatedfor[C21H25N3O]+requiresm/z335.1998,foundm/z335.1999.
实例3
(S,E)-N-(1-(6-(4-benzyl-4,5-dihydrooxazol-2-yl)pyridin-2-yl)ethylidene)-2,6-dimethylaniline(IIIc):yield86％；[α]D 20＝-2.5(c＝0.99,CHCl3)；[α]D 20＝-35.8(c＝1.00,PhCH3)；IR(neat):2922,1643,1573,1465,1371cm-1；1HNMR:(400.1MHz,CDCl3)δ8.51(dd,J＝8.0,0.8Hz,1H),8.16(dd,J＝7.6,0.8Hz,1H),7.88(dd,J＝8.0,7.6Hz,1H),7.36-7.20(m,5H),7.06(d,J＝7.6Hz,2H),6.93(t,J＝7.6Hz,1H),4.74-4.63(m,1H),4.46(dd,J＝9.2,8.4Hz,1H),4.26(dd,J＝8.4,8.0Hz,1H),3.32(dd,J＝14.0,5.2Hz,1H),2.78(dd,J＝14.0,9.0Hz,1H),2.26(s,3H),2.02(s,6H)；13CNMR:(100.6MHz,CDCl3)δ166.9,163.1,156.2,148.5,145.8,137.7,136.9,129.1,128.5,127.8,126.5,125.25,125.17,123.1,123.0,72.4,68.1,41.6,17.8,16.5；HRMS(EI)calculatedfor[C25H25N3O]+requiresm/z383.1998,foundm/z383.2000.
实例4
(E)-N-(1-(6-((IIIaS,8aR)-8,8a-dihydro-3aH-indeno[1,2-d]oxazol-2-yl)pyridin-2-yl)ethylidene)-2,6-diisopropylaniline(IIId):yield74％；M.p.174-175℃；[α]D 20＝-36.1(c＝1.11,CHCl3)；IR:3066,2961,2869,1638,1573,1459,1368；1HNMR:(400.1MHz,CDCl3)δ8.47(dd,J＝8.0,1.2Hz,1H),8.11(dd,J＝8.0,1.2Hz,1H),7.84(t,J＝8.0Hz,1H),7.59-7.63(m,1H),7.26-7.31(m,3H),7.13-7.18(m,2H),7.09(dd,J＝8.4,6.4Hz,1H),5.85(d,J＝8.0Hz,1H),5.61(ddd,J＝7.6,6.4,2.4Hz,1H),3.43-3.59(m,2H),2.63-2.76(m,2H),2.28(s,3H),1.12(d,J＝6.8Hz,12H)；13CNMR:(100.6MHz,CDCl3)δ166.8,163.2,156.2,146.3,146.0,141.5,139.8,136.9,135.66,135.65,128.6,127.5,125.7,125.4,125.3,123.6,123.1,122.9,83.9,77.2,39.8,28.2,23.18,23.17,22.8,17.3；HRMS(EI)calculatedfor[C29H31N3O]+requiresm/z437.2467,foundm/z437.2468.
实例5
(S,E)-N-(1-(6-(4-benzyl-4,5-dihydrooxazol-2-yl)pyridin-2-yl)ethylidene)-2,6-diethylaniline(IIIe):yield84％；[α]D 20＝-1.5(c＝1.02,CHCl3)；[α]D 20＝-37.9(c＝1.03,PhCH3)；IR(neat):3026,2965,1642,1573,1453,1370cm-1；1HNMR:(400.1MHz,CDCl3)δ8.51(dd,J＝8.0,1.2Hz,1H),8.16(dd,J＝7.6,1.2Hz,1H),7.87(dd,J＝8.0,7.6Hz,1H),7.35-7.20(m,5H),7.06-7.11(m,2H),7.00-7.05(m,1H),4.74-4.64(m,1H),4.46(dd,J＝9.2,8.6Hz,1H),4.26(dd,J＝8.6,7.6Hz,1H),3.32(dd,J＝13.6,5.2Hz,1H),2.78(dd,J＝13.6,8.8Hz,1H),2.46-2.29(m,4H),2.28(s,3H),1.13(t,J＝7.6Hz,6H)；13CNMR:(100.6MHz,CDCl3)δ166.7,163.1,156.3,147.6,145.8,137.7,137.0,131.0,129.2,128.6,126.6,125.9,125.3,123.3,123.1,72.5,68.1,41.7,24.5,16.9,13.6；HRMS(EI)calculatedfor[C27H29N3O]+requiresm/z411.2311,foundm/z411.2311.
实例6
(S,E)-N-(1-(6-(4-benzyl-4,5-dihydrooxazol-2-yl)pyridin-2-yl)ethylidene)-2,6-diisopropylaniline(IIIf):yield80％；M.p.128-129℃；[α]D 20＝-1.5(c＝1.04,CHCl3)；[α]D 20＝-33.7(c＝1.07,PhCH3)；>99％ee,determinedbyHPLC,HPLCconditions:ChiralcelOD-H,n-hexane/i-PrOH＝90/10,1.0mL/min,n＝254nm,tr5.1(minor),5.8(major)；IR(neat):2961,2926,1642,1574,1458,1370cm-1；1HNMR:(500.1MHz,CDCl3)δ8.52(dd,J＝7.5,0.8Hz,1H),8.17(dd,J＝8.0,0.5Hz,1H),7.90(dd,J＝8.0,7.5Hz,1H),7.35-7.30(m,2H),7.29-7.22(m,3H),7.19-7.14(m,2H),7.10(dd,J＝8.0,6.5Hz,1H),4.73-4.65(m,1H),4.48(dd,J＝8.5,8.0Hz,1H),4.28(dd,J＝8.0,7.5Hz,1H),3.33(dd,J＝14.0,5.0Hz,1H),2.79(dd,J＝14.0,8.5Hz,1H),2.75-2.68(m,1H),2.29(s,3H),1.14(d,J＝7.0Hz,12H)；13CNMR:(100.6MHz,CDCl3)δ166.7,163.2,156.3,146.3,145.9,137.8,137.0,135.7,135.6,129.2,128.6,126.6,125.3,123.6,123.2,123.0,72.5,68.2,41.7,28.2,23.2,22.8,17.2；HRMS(EI)calculatedfor[C29H33N3O]+requiresm/z439.2624,foundm/z439.2628.
实例7
(S,E)-N-(1-(6-(4-benzyl-4,5-dihydrooxazol-2-yl)pyridin-2-yl)ethylidene)-2-(tert-butyl)aniline(IIIg):yield89％；[α]D 20＝-0.4(c＝1.18,CHCl3)；[α]D 20＝-20.0(c＝0.93,PhCH3)；IR(neat):2956,2924,1638,1569,1455,1391,1371cm-1；1HNMR:(400.1MHz,CDCl3)δ8.44(dd,J＝7.8,1.2Hz,1H),8.15(dd,J＝7.8,1.2Hz,1H),7.88(t,J＝7.8Hz,1H),7.42(dd,J＝7.8,1.2Hz,1H),7.35-7.20(m,5H),7.18(td,J＝7.8,1.2Hz,1H),4.73-4.64(m,1H),4.46(dd,J＝9.2,8.6Hz,1H),4.26(dd,J＝8.6,7.6Hz,1H),3.32(dd,J＝13.6,5.0Hz,1H),2.78(dd,J＝13.6,9.2Hz,1H),2.44(s,3H),1.35(s,9H)；13CNMR:(100.6MHz,CDCl3)δ165.0,163.1,156.7,149.3,145.7,139.6,137.7,137.0,129.1,128.5,126.5,126.4,126.2,125.0,123.8,123.3,119.5,72.4,68.1,41.6,35.0,29.5,17.0；HRMS(EI)calculatedfor[C27H29N3O]+requiresm/z411.2311,foundm/z411.2315.
实例8
(S)-4-benzyl-2-(pyridin-2-yl)-4,5-dihydrooxoxazoline(IIIh):yield66％；[α]D 20＝+1.1(c＝0.96,CHCl3)；[α]D 20＝-44.6(c＝1.00,PhCH3)；>99％ee,determinedbyHPLC,HPLCconditions:ChiralcelOJ-H,n-hexane/i-PrOH＝90/10,1.0mL/min,n＝254nm,tr16.7(major),26.5(minor)；IR(neat):2923,2854,1641,1582,1471,1441,1363cm-1；1HNMR:(400.1MHz,CDCl3)δ8.73-8.69(m,1H),8.05(d,J＝7.6Hz,1H),7.76(td,J＝7.6,2.0Hz,1H),7.37(ddd,J＝7.6,4.8,1.2Hz,1H),7.34-7.19(m,5H),4.71-4.60(m,1H),4.44(dd,J＝9.2,8.8Hz,1H),4.22(dd,J＝8.8,8.0Hz,1H),3.29(dd,J＝13.8,5.2Hz,1H),2.76(dd,J＝13.8,9.2Hz,1H)；13CNMR:(100.6MHz,CDCl3)δ163.1,149.7,146.8,137.8,136.6,129.2,128.6,126.6,125.6,123.9,72.5,68.1,41.7；HRMS(EI)calculatedfor[C15H14N2O]+requiresm/z238.1106,foundm/z238.1108.
实例9
(S)-4-benzyl-2-(III-methylpyridin-2-yl)-4,5-dihydrooxoxazoline(IIIi):yield71％；[α]D 20＝-11.0(c＝1.01,CHCl3)；IR(neat):2959,2924,1642,1574,1453,1355cm-1；1HNMR:(400.1MHz,CDCl3)δ8.54(dd,J＝4.6,1.0Hz,1H),7.63-7.57(m,1H),7.36-7.20(m,6H),4.74-4.64(m,1H),4.40(dd,J＝9.4,8.6Hz,1H),4.18(dd,J＝8.6,7.8Hz,1H),3.27(dd,J＝13.6,5.6Hz,1H),2.79(dd,J＝13.6,8.8Hz,1H),2.62(s,3H)；13CNMR:(100.6MHz,CDCl3)δ162.8,146.8,145.5,139.2,137.9,135.0,129.2,128.5,126.5,124.7,71.2,68.7,41.8,20.5；HRMS(EI)calculatedfor[C16H16N2O]+requiresm/z252.1263,foundm/z252.1265.
实例10
(S)-4-benzyl-2-(4-methylpyridin-2-yl)-4,5-dihydrooxoxazoline(IIIj):yield65％；[α]D 20＝+7.6(c＝1.07,CHCl3)；IR(neat):2956,2923,1642,1475,1451,1353cm-1；1HNMR:(400.1MHz,CDCl3)δ8.55(d,J＝4.8Hz,1H),7.91(s,1H),7.35-7.19(m,6H),4.70-4.60(m,1H),4.44(dd,J＝9.2,8.8Hz,1H),4.22(t,J＝8.0Hz,1H),3.30(dd,J＝13.6,5.0Hz,1H),2.75(dd,J＝13.6,9.2Hz,1H),2.40(s,3H)；13CNMR:(100.6MHz,CDCl3)δ163.3,149.5,148.0,146.5,137.7,129.1,128.6,126.53,126.49,124.7,72.4,68.0,41.7,20.9；HRMS(EI)calculatedfor[C16H16N2O]+requiresm/z252.1263,foundm/z252.1260.
实例11
(S)-4-benzyl-2-(5-methylpyridin-2-yl)-4,5-dihydrooxoxazoline(IIIk):yield61％；[α]D 20＝+9.5(c＝1.04,CHCl3)；IR(neat):2922,1643,1569,1486,1452,1357cm-1；1HNMR:(400.1MHz,CDCl3)δ8.52(s,1H),7.94(d,J＝8.0Hz,1H),7.55(dd,J＝8.0,1.2Hz,1H),7.34-7.17(m,5H),4.70-4.58(m,1H),4.42(dd,J＝9.2,8.8Hz,1H),4.20(t,J＝8.0Hz,1H),3.29(dd,J＝13.6,4.8Hz,1H),2.75(dd,J＝13.6,8.8Hz,1H),2.37(s,3H)；13CNMR:(100.6MHz,CDCl3)δ162.9,149.9,143.8,137.6,136.7,135.5,128.9,128.3,126.2,123.2,72.1,67.7,41.4,18.2；HRMS(EI)calculatedfor[C16H16N2O]+requiresm/z252.1263,foundm/z252.1259.
实例12
(S)-4-benzyl-2-(6-methylpyridin-2-yl)-4,5-dihydrooxoxazoline(IIIl):yield62％；[α]D 20＝-0.2(c＝1.04,CHCl3)；[α]D 20＝-52.0(c＝1.00,PhCH3)；Lit9:[α]D 25＝-8.1(c＝0.8,CHCl3)；IR(neat):2923,2854,1641,1588,1495,1458,1365cm-1；1HNMR:(500.1MHz,CDCl3)δ7.88(d,J＝7.5Hz,1H),7.65(dd,J＝8.0,7.5Hz,1H),7.34-7.28(m,2H),7.27-7.20(m,4H),4.67-4.60(m,1H),4.43(dd,J＝9.5,9.0Hz,1H),4.23(dd,J＝8.5,8.0Hz,1H),3.31(dd,J＝14.0,5.0Hz,1H),2.74(dd,J＝13.5,8.0Hz,1H),2.64(s,3H)；13CNMR:(100.6MHz,CDCl3)δ163.1,158.6,146.0,137.7,136.6,129.0,128.4,126.3,125.2,121.0,72.3,67.8,41.5,24.4；HRMS(EI)calculatedfor[C16H16N2O]+requiresm/z252.1263,foundm/z252.1264.
实例13
(S)-4-benzyl-2-(4-(trifluoromethyl)pyridin-2-yl)-4,5-dihydrooxoxazoline(IIIm):yield72％；[α]D 20＝-1.7(c＝1.14,CHCl3)；[α]D 20＝-37.3(c＝0.99,PhCH3)；IR(neat):3030,2923,1644,1605,1571,1408,1328cm-1；1HNMR:(400.1MHz,CDCl3)δ8.89(d,J＝4.8Hz,1H),8.30(s,1H),7.62(d,J＝4.8Hz,1H),7.37-7.19(m,5H),4.76-4.65(m,1H),4.49(dd,J＝9.2,8.6Hz,1H),4.27(dd,J＝8.6,8.0Hz,1H),3.31(dd,J＝14.0,5.2Hz,1H),2.79(dd,J＝14.0,8.8Hz,1H)；13CNMR:(100.6MHz,CDCl3)δ162.1,150.7,148.0,139.2(q,JC-F＝34.3),137.4,129.2,128.6,126.7,122.4(q,JC-F＝271.8),121.0(q,JC-F＝3.6),119.8(q,JC-F＝3.6),72.8,68.2,41.5；19FNMR:(III76.5MHz,CDCl3)δ-183.3；HRMS(EI)calculatedfor[C16H13N2OF3]+requiresm/z306.0980,foundm/z306.0977.
实例14
(S)-(6-(4-benzyl-4,5-dihydrooxazol-2-yl)pyridin-2-yl)methanol(IIIn):yield45％；[α]D 20＝+1.8(c＝1.94,CHCl3)；IR(neat):3379,2922,1645,1583,1453,1366cm-1；1HNMR:(400.1MHz,CDCl3)δ7.89(d,J＝7.6Hz,1H),7.76(t,J＝7.6Hz,1H),7.52(d,J＝7.6Hz,1H),7.34-7.26(m,2H),7.26-7.19(m,3H),4.94-4.82(m,3H),4.67-4.55(m,1H),4.41(dd,J＝9.2,8.6Hz,1H),4.20(dd,J＝8.6,8.0Hz,1H),3.24(dd,J＝13.8,5.0Hz,1H),2.73(dd,J＝13.8,9.0Hz,1H)；13CNMR:(100.6MHz,CDCl3)δ163.2,160.8,145.3,137.4,137.2,129.1,128.5,126.5,122.6,122.3,72.4,67.7,64.6,41.4；HRMS(EI)calculatedfor[C16H16N2O2]+requiresm/z268.1212,foundm/z268.1214.
实例15
(S)-4-benzyl-2-(quinolin-2-yl)-4,5-dihydrooxoxazoline(IIIo):yield81％；[α]D 20＝-16.4(c＝1.01,CHCl3)；IR(neat):3060,3027,2923,1640,1596,1501,1371cm-1；1HNMR:(400.1MHz,CDCl3)δ8.27(d,J＝8.4Hz,1H),8.18(s,2H),7.78(d,J＝8.0Hz,1H),7.75-7.68(m,1H),7.58-7.51(m,1H),7.36-7.15(m,5H),4.76-4.63(m,1H),4.50(dd,J＝9.6,8.6Hz,1H),4.29(dd,J＝8.6,8.0Hz,1H),3.31(dd,J＝13.6,5.4Hz,1H),2.80(dd,J＝13.6,8.8Hz,1H)；13CNMR:(100.6MHz,CDCl3)δ163.4,147.6,146.8,137.7,136.7,130.4,130.0,129.2,128.8,128.6,127.9,127.5,126.6,120.8,72.7,68.2,41.7；HRMS(EI)calculatedfor[C19H16N2O]+requiresm/z288.1263,foundm/z288.1265.
实例16
(S)-4-benzyl-2-(pyrazin-2-yl)-4,5-dihydrooxoxazoline(IIIp):yield55％；[α]D 20＝-2.0(c＝1.05,CHCl3)；Lit11:[α]D＝-18.5(c＝1.035,CHCl3)；IR(neat):3027,2924,2855,1646,1525,1472,1358cm-1；1HNMR:(400.1MHz,CDCl3)δ9.27(d,J＝1.6Hz,1H),8.70-8.65(m,2H),7.34-7.20(m,5H),4.76-4.66(m,1H),4.47(dd,J＝9.6,8.4Hz,1H),4.25(dd,J＝8.4,7.8Hz,1H),3.29(dd,J＝14.0,5.2Hz,1H),2.80(dd,J＝14.0,8.6Hz,1H)；13CNMR:(100.6MHz,CDCl3)δ161.2,146.1,145.1,144.0,142.3,137.2,129.1,128.4,126.5,72.4,68.0,41.3.
实例17
(S)-4-benzyl-2-(pyrimidin-2-yl)-4,5-dihydrooxoxazoline(IIIq):yield46％；[α]D 20＝+12.9(c＝1.79,CHCl3)；IR(neat):3030,2921,1648,1562,1495,1432,1362cm-1；1HNMR:(400.1MHz,CDCl3)δ8.89(d,J＝4.8Hz,2H),7.42(t,J＝5.0Hz,1H),7.36-7.19(m,5H),4.81-4.69(m,1H),4.51(dd,J＝9.2,8.6Hz,1H),4.29(dd,J＝8.6,8.0Hz,1H),3.39(dd,J＝13.8,5.0Hz,1H),2.80(dd,J＝13.8,9.4Hz,1H)；13CNMR:(100.6MHz,CDCl3)δ161.6,157.3,155.5,137.2,128.9,128.3,126.3,121.9,72.6,68.0,41.0；HRMS(EI)calculatedfor[C14H13N3O]+requiresm/z239.1059,foundm/z239.1057.
实例18
(S)-2-(benzo[d]thiazol-2-yl)-4-benzyl-4,5-dihydrooxoxazoline(IIIr):yield46％；[α]D 20＝+42.9(c＝1.11,CHCl3)；IR(neat):3028,2924,2855,1645,1505,1455,1368cm-1；1HNMR:(400.1MHz,CDCl3)δ8.18(d,J＝8.0Hz,1H),7.94(d,J＝8.4Hz,1H),7.59-7.46(m,2H),7.36-7.20(m,5H),4.78-4.66(m,1H),4.52(dd,J＝9.2,8.8Hz,1H),4.31(dd,J＝8.8,7.6Hz,1H),3.30(dd,J＝13.6,5.0Hz,1H),2.83(dd,J＝13.6,8.8Hz,1H)；13CNMR:(100.6MHz,CDCl3)δ159.1,155.6,153.2,137.1,135.9,129.2,128.6,126.9,126.8,126.7,124.7,121.7,73.0,68.2,41.2；HRMS(EI)calculatedfor[C17H14N2OS]+requiresm/z294.0827,foundm/z294.0823.
实例19
(S)-4-benzyl-2-(5-chloro-3-methylbenzo[b]thiophen-2-yl)-4,5-dihydrooxoxazoline(IIIs):yield95％；M.p.95-96℃；[α]D 20＝+35.8(c＝1.03,CHCl3)；IR(neat):3026,2923,1635,1561,1531,1454,1376cm-1；1HNMR:(400.1MHz,CDCl3)δ7.73-7.67(m,2H),7.37-7.20(m,6H),4.65-4.46(m,1H),4.35(dd,J＝9.2,8.4Hz,1H),4.16(dd,J＝8.4,8.0Hz,1H),3.24(dd,J＝13.6,5.2Hz,1H),2.75(dd,J＝13.6,8.6Hz,1H),2.66(s,3H)；13CNMR:(100.6MHz,CDCl3)δ160.3,141.6,137.8,137.7,135.9,130.6,129.2,128.5,126.5,126.1,123.4,122.6,71.9,67.9,41.6,13.1；HRMS(EI)calculatedfor[C19H16NOSCl]+requiresm/z341.0641,foundm/z341.0642.
实例20
(S)-4-benzyl-2-(6'-bromo-[2,2'-bipyridin]-6-yl)-4,5-dihydrooxoxazoline(IIIt):yield30％；M.p.133-135℃；[α]D 20＝-12.0(c＝1.04,CHCl3)；IR(neat):3062,2921,1641,1574,1550,1420,1369cm-1；1HNMR:(400.1MHz,CDCl3)δ8.52(dd,J＝7.6,5.2Hz,2H),8.09(d,J＝7.6Hz,1H),7.90(dd,J＝8.0,7.6Hz,1H),7.66(t,J＝7.6Hz,1H),7.49(d,J＝7.6Hz,1H),7.37-7.19(m,5H),4.74-4.62(m,1H),4.47(dd,J＝9.2,8.6Hz,1H),4.27(dd,J＝8.6,8.0Hz,1H),3.32(dd,J＝13.6,4.8Hz,1H),2.78(dd,J＝13.6,9.0Hz,1H)；13CNMR:(100.6MHz,CDCl3)δ163.1,156.4,154.5,146.3,141.4,139.2,137.7,137.6,129.2,128.6,128.3,126.6,124.5,123.3,120.3,72.5,68.1,41.6；HRMS(EI)calculatedfor[C20H16BrN3O]+requiresm/z393.0477,foundm/z393.0470.
实例21
(S)-4-benzyl-2-(4-methoxyphenyl)-4,5-dihydrooxoxazoline(IIIu):yield92％；[α]D 20＝+17.9(c＝0.99,CHCl3)；Lit12:[α]10＝+12.8(c＝0.641,CHCl3)；IR(neat):2903,2840,1645,1609,1512,1359,1310cm-1；1HNMR:(400.1MHz,CDCl3)δ7.92-7.86(m,2H),7.34-7.18(m,5H),6.94-6.87(m,2H),4.60-4.49(m,1H),4.30(dd,J＝9.2,8.4Hz,1H),4.11(dd,J＝8.4,7.6Hz,1H),3.83(s,3H),3.24(dd,J＝13.6,5.2Hz,1H),2.71(dd,J＝13.6,9.0Hz,1H)；13CNMR:(100.6MHz,CDCl3)δ163.7,162.0,138.1,129.9,129.2,128.5,126.4,120.2,113.6,71.7,67.8,55.3,41.9；HRMS(EI)calculatedfor[C17H17NO2]+requiresm/z267.1259,foundm/z267.1252.
实例22
(S)-4-benzyl-2-(4-fluorophenyl)-4,5-dihydrooxoxazoline(IIIv):yield93％；[α]D 20＝+1.0(c＝1.08,CHCl3)；[α]D 20＝-40.3(c＝1.00,PhCH3)；Lit12:[α]D 20＝+10.1(c＝0.801,CHCl3)；>99％ee,determinedbyHPLC,HPLCconditions:ChiralcelOD-H,n-hexane/i-PrOH＝90/10,1.0mL/min,n＝254nm,tr5.3(minor),6.5(major)；IR(neat):2924,1651,1605,1510,1358cm-1；1HNMR:(400.1MHz,CDCl3)δ7.98-7.91(m,2H),7.34-7.28(m,2H),7.27-7.20(m,3H),7.20-7.05(m,2H),4.62-4.52(m,1H),4.35(dd,J＝9.6,8.4Hz,1H),4.14(dd,J＝8.4,7.2Hz,1H),3.23(dd,J＝13.6,5.2Hz,1H),2.73(dd,J＝13.6,8.8Hz,1H)；HRMS(EI)calculatedfor[C16H14NOF]+requiresm/z255.1059,foundm/z255.1057.
实例23
(S)-2-(4-benzyl-4,5-dihydrooxazol-2-yl)benzonitrile(IIIw):yield95％；M.p.74-76℃；[α]D 20＝-15.5(c＝1.01,CHCl3)；,IR(neat):3027,2853,2228,1653,1494,1453,1359cm-1；1HNMR:(400.1MHz,CDCl3)δ7.99(dd,J＝7.6,1.2Hz,1H),7.74(dd,J＝7.6,1.2Hz,1H),7.61(td,J＝7.6,1.2Hz,1H),7.53(td,J＝7.6,1.2Hz,1H),7.34-7.25(m,4H),7.25-7.19(m,1H),4.72-4.62(m,1H),4.41(dd,J＝9.2,8.6Hz,1H),4.20(dd,J＝8.6,8.0Hz,1H),3.23(dd,J＝13.6,5.6Hz,1H),2.80(dd,J＝13.6,8.0Hz,1H)；13CNMR:(100.6MHz,CDCl3)δ161.3,137.5,134.6,132.4,131.1,130.1,129.3,128.5,126.6,117.8,111.7,72.3,68.2,41.4；HRMS(EI)calculatedfor[C17H14N2O]+requiresm/z262.1106,foundm/z262.1107.
实例24
(S)-4-benzyl-2-(2-fluorophenyl)-4,5-dihydrooxoxazoline(IIIx):yield91％；[α]D 20＝-21.7(c＝1.00,CH2Cl2)；IR(neat):2923,2854,1647,1612,1495,1455,1358cm-1；1HNMR:(400.1MHz,CDCl3)δ7.85(td,J＝7.6,1.6Hz,1H),7.44-7.36(m,1H),7.32-7.18(m,5H),7.18-7.08(m,2H),4.66-4.56(m,1H),4.29(dd,J＝9.2,8.6Hz,1H),4.11(dd,J＝8.6,7.6Hz,1H),3.26(dd,J＝13.6,5.0Hz,1H),2.74(dd,J＝13.6,9.0Hz,1H)；13CNMR:(100.6MHz,CDCl3)δ161.0(d,JC-F＝256.7),160.5(d,JC-F＝5.1),137.6,132.7(d,JC-F＝8.7),130.9(d,JC-F＝1.4),129.1,128.4,126.4,123.7(d,JC-F＝3.6),116.5(d,JC-F＝21.9),115.9(d,JC-F＝10.2),71.2,67.8,41.4；19FNMR:(III76.5MHz,CDCl3)δ-109.3；HRMS(EI)calculatedfor[C16H14NOF]+requiresm/z255.1059,foundm/z255.1055.
实例25
(S)-2-([1,1'-biphenyl]-2-yl)-4-benzyl-4,5-dihydrooxazole(IIIy):yield88％；[α]D 20＝-43.4(c＝1.03,CHCl3)；IR(neat):3057,1657,1590,1484,1438,1311cm-1；1HNMR:(400.1MHz,CDCl3)δ7.75(dd,J＝8.0,1.6Hz,1H),7.47(ddd,J＝8.0,7.6,1.6Hz,1H),7.38(dd,J＝7.2,1.2Hz,1H),7.29-7.37(m,6H),7.24-7.29(m,2H),7,17-7.23(m,1H),7.12-7.17(m,2H),4.39-4.48(m,1H),4.06(dd,J＝9.2,8.4Hz,1H),3.82(dd,J＝8.4,7.6Hz,1H),3.04(dd,J＝13.2,5.2Hz,1H),2.69(dd,J＝13.2,8.4Hz,1H)；13CNMR:(100.6MHz,CDCl3)δ165.4,141.8,141.1,137.8,130.4,130.2,130.0,129.3,128.4,128.3,127.9,127.6,127.1,127.0,126.4,71.8,67.7,41.2；HRMS(EI)calculatedfor[C22H19NO]+requiresm/z313.1467,foundm/z313.1471.
实例26
(S)-4-benzyl-2-(2-(pyridin-2-yl)phenyl)-4,5-dihydrooxazole(IIIz):yield75％；[α]D 20＝-38.8(c＝1.04,CHCl3)；IR(neat):3393,3060,3028,2923,1654,1587,1465cm-1；1HNMR:(400.1MHz,CDCl3)δ8.65(dq,J＝4.8,0.8Hz,1H),7.83(dd,J＝8.0,0.8Hz,1H),7.65(ddd,J＝7.6,7.6,2.0Hz,1H),7.59(dd,J＝7.6,1.2Hz,1H),7.53(ddd,J＝7.6,7.6,1.2Hz,1H),7.45(ddd,J＝7.6,7.6,1.2Hz,1H),7.36(ddd,J＝8.0,0.8,0.8Hz,1H),7.26-7.32(m,2H),7.15-7.25(m,4H),4.41-4.46(m,1H),4.10(dd,J＝9.2,8.4Hz,1H),3.88(dd,J＝8.4,7.6Hz,1H),3.09(dd,J＝14.0,5.2Hz,1H),2.73(dd,J＝14.0,8.4Hz,1H)；13CNMR:(100.6MHz,CDCl3)δ165.2,158.8,149.0,140.7,137.9,135.8,130.6,130.2,129.9,129.3,128.4,128.2,127.6,126.4,123.2,121.9,71.8,67.8,41.2；HRMS(EI)calculatedfor[C21H18N2O]+requiresm/z314.1419,foundm/z314.1413.
实例27
(S,E)-4-benzyl-2-styryl-4,5-dihydrooxoxazoline(IIIaa):yield67％；M.p.78-80℃；[α]D 20＝+0.9(c＝1.14,CHCl3)；[α]D 20＝-58.2(c＝1.07,CH2Cl2)；Lit14:[α]D 20＝-7.4(c＝1.21,MeOH)；>99％ee,determinedbyHPLC,HPLCconditions:ChiralcelOJ-H,n-hexane/i-PrOH＝90/10,1.0mL/min,n＝254nm,tr11.4(minor),12.6(major)；IR(neat):3060,2922,1952,1652,1605,1495,1362cm-1；1HNMR:(400.1MHz,CDCl3)δ7.46(d,J＝6.8Hz,2H),7.39-7.26(m,6H),7.25-7.17(m,3H),6.65(d,J＝16.4Hz,1H),4.56-4.44(m,1H),4.25(dd,J＝8.8,8.6Hz,1H),4.02(dd,J＝8.6,7.6Hz,1H),3.15(dd,J＝13.6,5.4Hz,1H),2.70(dd,J＝13.6,8.4Hz,1H)；13CNMR:(100.6MHz,CDCl3)δ163.6,139.9,137.8,135.1,129.3,129.0,128.7,128.4,127.3,126.4,115.1,71.4,67.6,41.6；HRMS(EI)calculatedfor[C18H17NO]+requiresm/z263.1310,foundm/z263.1303.
实例28
(S)-4-benzyl-2-(2-(diphenylphosphino)phenyl)-4,5-dihydrooxazole(IIIab):yield56％,[α]D 20＝+24.6(c＝1.250,CHCl3)；1HNMR:(400.1MHz,CDCl3)δ7.86(dd,J＝7.2,2.8Hz,1H),7.26-7.40(m,12H),7.20-7.25(m,2H),7.14-7.20(m,1H),7.07(d,J＝7.2Hz,1H),6.86(dd,J＝7.2,4.4Hz,1H),4.29-4.39(m,1H),4.03(dd,J＝9.2,8.4Hz,1H),3.77(t,J＝8.0Hz,1H),2.91(dd,J＝14.0,4.8Hz,1H),2.11(dd,J＝14.0,9.2Hz,1H)；31PNMR:(162.0MHz,CDCl3)δ-4.7.
实例29
(S)-2-(4-benzyl-4,5-dihydrooxazol-2-yl)phenol(8a)：yield56％；[α]D 20＝-6.65(c＝1.045,CHCl3)；1HNMR:(400.1MHz,CDCl3)δ12.16(br,1H),7.61(dd,J＝8.0,1.6Hz,1H),7.36(ddd,J＝8.4,7.2,1.6Hz,1H),7.30(dd,J＝7.6,1.2Hz,2H),7.20-7.26(m,3H),7.00(dd,J＝8.4,0.8Hz,1H),6.85(ddd,J＝7.6,7.6,0.8Hz,1H),4.55-4.65(m,1H),4.37(dd,J＝8.8,8.4Hz,1H),4.11(dd,J＝8.4,7.2Hz,1H),3.09(dd,J＝13.2,9.3Hz,1H),2.80(dd,J＝13.2,7.6Hz,1H).
实例30
(S)-2-(4-benzyl-4,5-dihydrooxazol-2-yl)aniline(IIIad)：yield87％；[α]D 20＝+48.1(c＝0.98,CHCl3)；Lit17:[α]D＝+24.7(c＝1.00,CHCl3)；1HNMR:(400.1MHz,CDCl3)δ7.67(dd,J＝8.0,1.2Hz,1H),7.26-7.33(m,2H),7.15-7.26(m,4H),6.60-6.70(br,2H),6.07(s,2H),4.53-4.63(m,1H),4.25(dd,J＝9.2,8.4Hz,1H),4.00(dd,J＝8.4,7.6Hz,1H),3.11(dd,J＝14.0,6.0Hz,1H),2.74(dd,J＝14.0,8.0Hz,1H).
以上例举的仅是本发明的优选实施方式，本发明并不限于以上实施例，本领域技术人员在不脱离本发明的精神和构思的前提下直接导出或联想到的其他改进和变化，均应认为包含在本发明的保护范围内。

Claims (9)

1.一种含2-取代噁唑啉衍生物的制备方法，其特征在于，在有机溶剂中，将式I所示的卤化物，式II所示的噁唑啉环，钯催化剂，配体与碱以1:1-2.0:1％-50mol％:1％-50mol％:1-5的配比混合均匀，在0-150℃温度下反应24-72小时，分离纯化，得到式III所示的2-取代的噁唑啉化合物，合成路线如下所示：
式I和式III中R1为C1-C6的烷基，环烷基，羟基，C1-C6的烷氧基，羟甲基，氰基，卤素，二芳基磷基，亚胺基，胺基，氨烷基；式II和式III中R2，R3和R4为C1-C6的烷基，环烷基，芳基；式I和式III中X为卤素,类卤素，Y为N或C。
2.根据权利要求1所述的含2-取代噁唑啉衍生物的制备方法，其特征在于，所述的钯催化剂为Pd(PPh3)4，PdCl2，PdCl2(PPh3)2，Pd(OAc)2，Pd(PPh3)2Cl2，Pd2(dba)3·CHCl3任意一种，所述配体为单磷配体和双膦配体，所述碱为无机碱，所述有机溶剂为高沸点非极性溶剂。
3.根据权利要求1或2所述的含2-取代噁唑啉衍生物的制备方法，其特征在于，式I所示的卤化物与式II所示的噁唑啉环，钯催化剂，配体，碱摩尔比优选1:1.2-1.5:2.5-10mol％:2.8-12mol％,2.0-4.0。
4.根据权利要求1所述的含2-取代噁唑啉衍生物的制备方法，其特征在于，所述的X优选Cl，Br。
5.根据权利要求1或2所述的含2-取代噁唑啉衍生物的制备方法，其特征在于，所述的Pd优选Pd(OAc)2。
6.根据权利要求1或2所述的含2-取代噁唑啉衍生物的制备方法，其特征在于，所述的配体优选dppe。
7.根据权利要求3所述的含2-取代噁唑啉衍生物的制备方法，其特征在于，所述的碱优选叔丁醇锂。
8.根据权利要求1或2或4所述的含2-取代噁唑啉衍生物的制备方法，其特征在于，所述的碱优选叔丁醇锂。
9.根据权利要求1或2所述的含2-取代噁唑啉衍生物的制备方法，其特征在于，所述的有机溶剂优选1,4-二氧六环。
CN201510745883.3A 2015-11-04 2015-11-04 一种含2-取代噁唑啉衍生物的制备方法 Pending CN105601626A (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201510745883.3A CN105601626A (zh) 2015-11-04 2015-11-04 一种含2-取代噁唑啉衍生物的制备方法

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN201510745883.3A CN105601626A (zh) 2015-11-04 2015-11-04 一种含2-取代噁唑啉衍生物的制备方法

Publications (1)

Publication Number Publication Date
CN105601626A true CN105601626A (zh) 2016-05-25

Family

ID=55982047

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201510745883.3A Pending CN105601626A (zh) 2015-11-04 2015-11-04 一种含2-取代噁唑啉衍生物的制备方法

Country Status (1)

Country Link
CN (1) CN105601626A (zh)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106243099A (zh) * 2016-06-28 2016-12-21 浙江大学 一种镍催化的新型含氮三齿配体合成的方法
CN106582849A (zh) * 2016-12-26 2017-04-26 东莞市联洲知识产权运营管理有限公司 一种用于不对称烯丙基烷基化反应的催化剂及其制备方法
CN108774216A (zh) * 2018-02-11 2018-11-09 尚谷科技（天津）有限公司 一种单齿配位噁唑啉配体及其制备方法和应用

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101712656A (zh) * 2009-12-23 2010-05-26 北京理工大学 一种噁唑啉西佛碱配体及其制备方法
WO2012074126A1 (en) * 2010-11-30 2012-06-07 Takeda Pharmaceutical Company Limited Bicyclic compound
CN104447725A (zh) * 2014-10-22 2015-03-25 浙江大学 一种手性含亚胺吡啶噁唑啉的化合物及其制备方法

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101712656A (zh) * 2009-12-23 2010-05-26 北京理工大学 一种噁唑啉西佛碱配体及其制备方法
WO2012074126A1 (en) * 2010-11-30 2012-06-07 Takeda Pharmaceutical Company Limited Bicyclic compound
CN104447725A (zh) * 2014-10-22 2015-03-25 浙江大学 一种手性含亚胺吡啶噁唑啉的化合物及其制备方法

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
I SMARI，等: "Reactivity of bromofluorenes in palladium-catalysed direct arylation of heteroaromatics", 《CATALYSIS SCIENCE & TECHNOLOGY》 *
J ROGER，等: "Carbonates: Ecofriendly Solvents for Palladium‐Catalyzed Direct 2‐Arylation of Oxazole Derivatives", 《CHEMSUSCHEM》 *

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106243099A (zh) * 2016-06-28 2016-12-21 浙江大学 一种镍催化的新型含氮三齿配体合成的方法
CN106243099B (zh) * 2016-06-28 2019-01-15 浙江大学 一种镍催化的新型含氮三齿配体合成的方法
CN106582849A (zh) * 2016-12-26 2017-04-26 东莞市联洲知识产权运营管理有限公司 一种用于不对称烯丙基烷基化反应的催化剂及其制备方法
CN108774216A (zh) * 2018-02-11 2018-11-09 尚谷科技（天津）有限公司 一种单齿配位噁唑啉配体及其制备方法和应用

Similar Documents

Publication Publication Date Title
JP5041501B2 (ja) アミド化合物を配位子とする遷移金属錯体を用いたアルコールの製造方法
CN105601626A (zh) 一种含2-取代噁唑啉衍生物的制备方法
Quan et al. The synthesis of chiral β-aryl-α, β-unsaturated amino alcohols via a Pd-catalyzed asymmetric allylic amination
Tarui et al. Ni-catalyzed α-arylation of secondary α-bromo-α-fluoro-β-lactam: cross-coupling of a secondary fluorine-containing electrophile
CA2810478A1 (en) Processes for the preparation of 4-{4-[5(s)-(aminomethyl)-2-oxo-1,3-oxazolidin-3-yl]phenyl}morpholin-3-one
Wang et al. Synthesis of enantiopure 1, 2-azido and 1, 2-amino alcohols via regio-and stereoselective ring-opening of enantiopure epoxides by sodium azide in hot water
Liu et al. Stereodivergent asymmetric hydrogenation of quinoxalines
Allais et al. Early clinical development of lufotrelvir as a potential therapy for COVID-19
WO2004002925A2 (en) Process for preparing (r)-aryloxypropionic acid ester derivatives
CN108586376A (zh) 一种由碘化亚铜制备碘代苯并噁嗪的方法
CN111440205B (zh) 一种联硼酸二醇酯、其制备方法、其中间体及其应用
JPH04275258A (ja) 光学活性１−アリール−アルキルアミン類のラセミ化方法
JP2001048864A (ja) β−アドレナリン受容体アゴニストの製造用化合物と方法
CN106588787B (zh) 一种含芳甲酰基1,2,3-三氮唑类配体的应用
CN110105294A (zh) 一种多取代四氢喹喔啉衍生物的制备方法
DK2526081T3 (en) METHOD OF PRODUCING aryl and HETEROARYLEDDIKESYREDERIVATER
CN101481369A (zh) 一种合成4,6位取代3,-4-二氢-吡喃-2-酮衍生物的方法
WO2021002407A1 (ja) フルオロアルキル基含有化合物とその製造方法
JP2003300940A (ja) ビアリール化合物の製造法
CN102791661A (zh) 二氟环丙烷化合物的制造方法
JPH10310563A (ja) オキサゾリンを用いるクロロケトンの製造方法
CN111943930A (zh) Lasmiditan的合成工艺
CN111018807A (zh) 一种合成1,2,4-噻二唑衍生物的方法
CN104311559A (zh) 一类光学纯手性环状n,n-缩醛的合成方法
CN111943967B (zh) 一种合成烯基硼酸酯类化合物的方法

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
RJ01 Rejection of invention patent application after publication

Application publication date: 20160525

RJ01 Rejection of invention patent application after publication